JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | H. Ahmed, Hanaa | |
| dc.contributor.author | M. Metwally, Fateheya | |
| dc.contributor.author | Rashad, Hend | |
| dc.contributor.author | M. Zaazaa, Asmaa | |
| dc.contributor.author | M. Ezzat, Shahira | |
| dc.contributor.author | M. Salama, Maha | |
| dc.date.accessioned | 2019-10-19T12:12:11Z | |
| dc.date.available | 2019-10-19T12:12:11Z | |
| dc.date.issued | 2014 | |
| dc.identifier.citation | 1. WHO, Obesity and overweight, WHO: World Health Organization, 2013. 2. Graves BW, The obesity epidemic: scope of the problem and management strategies, J Midwifery Womens Health, 55(6), 2010, 568–78. 3. Heal DJ, Gosden J, Smith SL, A review of late-stage CNS drug candidates for the treatment of obesity, International Journal of Obesity, 37, 2013, 107-117 4. Mackenbach JP, Stirbu I, Roskam AJR, Schaap MM, Menvielle G, Leinsalu M, Socioeconomic inequalities in health in 22 European countries, N Engl J Med, 358, 2008, 2468—81. 5. Chao C, Shih C, Wang C, Wu J, Lu F, Chang C, Yang Y, Low socioeconomic status may increase the risk of central obesity in incoming university students in Taiwan, Obesity Research & Clinical Practice, 8, 2014, 212-219. 6. Mun EC, Blackburn GL, Matthews JB, Current status of medical and surgical therapy for obesity, Gastroenterology, 120 (3), 2001, 669–681. 7. Wooding AE, Rehman I, Obesity and prostate cancer: Is there a link, e-SPEN Journal, 9, 2014, e123ee130. 8. McGovern L, Johnson JN, Paulo R, Hettinger A, Singhal V, Kamath C, Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials, J Clin Endocrinol Metab., 93, 2008, 4600–4605. 9. Chaput JP, St-Pierre S, Tremblay A, Currently available drugs for the treatment of obesity: sibutramine and orlistat, Mini Rev Med Chem., 7, 2007, 3–10. 10. Thurairajah PH, Syn WK, Neil DA, Stell D, Haydon G, Orlistat (xenical)-induced subacute liver failure, Eur J Gastroenterol Hepatol., 17, 2005, 1437–1438. 11. Drew BS, Dixon AF, Dixon JB, Obesity management: Update on orlistat, Vasc Health Risk Manag, 3, 2007, 817–821. 12. Poston WS, Foreyt JP, Sibutramine and the management of obesity, Expert Opin Pharmacother., 5, 2004, 633–642. 13. Tziomalos K, Krassas GE, Tzotzas T, The use of sibutramine in the management of obesity and related disorders: an update, Vasc Health RisManag, 5, 2009, 441–452. 14. Slovacek L, Pavlik V, Slovackova B, The effect of sibutramine therapy on occurrence of depression symptoms among obese patients, Nutr Metab Cardiovasc Dis., 18, 2008, e43–e44. 15. Karamadoukis L, Shivashankar GH, Ludeman L Williams AJ, An unusual complication of treatment with orlistat, Clin Nephrol., 71, 2009, 430–432. 16. Halford JC, Obesity drugs in clinical development, Curr Opin Invest Drugs, 7, 2006, 312–318. 17. Melnikova I, Wages D, Anti-obesity therapies, Nat Rev Drug Discov., 5, 2006, 369–370. 18. Nakayama T, Suzuki S, Kudo H, Sassa S, Nomura M, Sakamoto S, Effects of three Chinese herbal medicines on plasma and liver lipids in mice fed a highfat diet, J Ethnopharmacol., 109, 2007, 236–240. 19. Mayer MA, Hocht C, Puyo A, Taira CA, Recent advances in obesity pharmacotherapy, Curr Clin Pharmacol, 4, 2009, 53– 61. 20. Han LK, Kimura Y, Okuda H, Anti-obesity effects of natural products, Stud Nat Prod Chem., 30, 2005, 79–110. 21. Rayalam S, Della-Fera MA, Baile CA, Phytochemicals and regulation of the adipocyte life cycle, J Nutr Biochem., 19, 2008, 717–726. 22. Ramachandran C, Peter KV, Gopalakrishan PK, Drumstick (Moringa oleifera). A multi-purpose Indian vegetable, Economic Botany, 34(3), 1980, 276–282. 23. Sofowora A, Medicinal plants and traditional medicine in Africa. John Wiley and Sons Ltd, New York, 1982, 214–218. 24. Ghasi S, Nwobodo E, Ofili JO, Hypocholesterolemic effects of crude extract of leaf of Moringa oleifera Lam in high fat diet fed wistar rats, Journal of Ethnopharmacology, 69(1), 2000, 21- 25. 25. Dangi SY, Jolly CI, Narayanan S, Antihypertensive activity of the total alkaloids from the leaves of Moringa oleifera, J pharmaceutical biology, 40(2), 2002, 144-148. 26. Soliman MM, Attia HF, El-Shazly SA, Saleh OM, Biomedical effects of cinnamon extract on obesity and diabetes relevance in Wistar rats, Am J Biochem Mol Biol., 2, 2012, 133-145. 27. Novelli EL, Diniz YS, Galhardi CM, Ebaid GM, Rodrigues HG, Anthropometrical parameters and markers of obesity in rats, Lab Anim., 41, 2007, 111-119. 28. Jain PG, Patil SD, Haswani NG, Girase MV, Surana SJ, Hypolipidemic activity of Moringa oleifera Lam., Moringaceae, on high fat diet induced hyperlipidemia in albino rats, Brazilian Journal of Pharmacognosy, 20(6), 2010, 969-973. 29. Mbikay M, Therapeutic potential of Moringa olifera leaves in chronic hyperglycemia and dyslipidemia: a review, Frontiers in pharmacology, 3(24), 2012, 1-12. 30. Meiattini F, The 4-hydroxybenzoate/4-aminophenazone chromogenic system, Clin Chem., 24(12), 1978, 2161-2165. 31. Buccolo G, Quantitative determination of serum triglycerides by use of enzymes, Clin Chem., 19(5), 1973, 476-482. 32. Naito HK, HDL Cholesterol, Kaplan A, Clin Chem The C.V. Mosby Co. St Louis, Toronto, Princeton, 1984, 1207-1213 and 437. 33. Wieland H, Seidel D, J-Lipid Res., 24, 1983, 904. 34. Satoh K, Serum lipid peroxide in Cerebrovascular disorders determined by a new colorimetric method, Clinica Chimica Acta, 90, 1978, 37-43. 35. Montgoery HAC, Dymock JF, Analyst, 86, 1961, 414. 36. Yun JW, Possible anti-obesity therapeutics from nature – A review, Phytochemistry, 71, 2010, 1625–1641. 37. Rodrigues A, Pereira PC, Vicente AF, Brito JA, Bernardo MA, Mesquita MF, Food intake, body mass index and body fat mass in elderly, Asian J Clin Nutr., 4, 2012, 107-115. 38. Dongmeza E, Siddhuraju P, Francis G, Becker K, Effects of dehydrated methanol extracts of moringa (Moringa oleifera Lam.) leaves and three of its fractions on growth performance and feed nutrient assimilation in Nile tilapia (Oreochromis niloticus (L.), Aquaculture, 261, 2006, 407–422. 39. Koh KK, Quon MJ, Han SH, Lee Y, Kim, SJ, Park JP Shin EK, Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients, Atherosclerosis, 204, 2009, 483–490. 40. Ballantyne, CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J, Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S, Circulation, 104, 2001, 3046-3051. 41. Son EL, Pal UK, Mandal PK, Hong GE, Kim SK, Lee CH, Hypolipidaemic effect of processed sulfur, Allium tuberosum rottl. and fermented Allium tuberosum rottl in rat, Asian J Anim Vet Adv., 7, 2012, 812-821. 42. Fruchart JC, Brewer HB, Leitersdorf E, Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group, Am J Cardiol., 81, 1998, 912-917. 43. Raveh O, Pinchuk I, Fainaru M, Lichtenberg D, Kinetics of lipid peroxidation in mixture of HDL and LDL, mutual effects, Free Radic Biol Med., 31, 2001, 1486-1497. 44. Hassarajani S, Souza TD, Mengi SA, Efficacy study of the bioactive fraction (F-3) of Acorus calamus in hyperlipidemia, Indian J Pharmacol, 39, 2007, 196-200. 45. Anwar F, Latif S, Ashraf M, Gilani AH, Review Moringa oleifera: A food plant with multiple medicinal uses, Phytotherapy Res., 21(1), 2007, 17-25. 46. Saluja MP, Kapil RS, Popli SP, Studies in medicinal plants: part VI. Chemical constituents of Moringa oleifera Lamk. (hybrid variety) and isolation of 4-hydroxymellein, Indian Journal of Chemistry, 16(11), 1978, 1044–1045. 47. Kane JP, Malloy MJ, Treatment of hypercholesterolemia, Medical Clinics of North America, 66, 1982, 537–550. 48. O’Byme DJ, Devaraj S, Grundy SM, Jialal I, Comparison of antioxidant effects of Concord grape juice flavonoids and α- tocopherol on markers of oxidative stress in healthy adults, Am J Clin Nutr., 76, 2002, 1367–1374. 49. Matikainen N, Kahri J, Taskinen MR, “Reviewing statin therapy in diabetes—towards the best practice,” Primary Care Diabetes, 4 (1), 2010, 9–15. 50. Yao XM, Ye SD, Zai Z, “Simvastatin protects diabetic rats against kidney injury through the suppression of renal matrix | en_US |
| dc.identifier.issn | 0976 – 044X | |
| dc.identifier.other | https://doi.org/ | |
| dc.identifier.uri | https://cutt.ly/GtwjiOs | |
| dc.description | MSA Google Scholar | |
| dc.description.abstract | Obesity is a condition in which excess body fat is accumulated to an extent that health may be negatively affected. Obesity is associated with a number of chronic health problems such as diabetes, heart disease, hypertension and cancer. The current study was constructed to evaluate the efficacy of alcoholic extract of Moringa oleifera in management of obesity induced by high cholesterol diet in rats. Adult female albino rats were classified into four groups. The first group was kept on standard rodent chow for 30 weeks (lean control). The other three groups received high cholesterol diet for 30 weeks. These animals were assigned as obese control group, Moringa oleifera treated group and Simvastatin treated group. The results revealed significant increase in thoracic (TC) and abdominal (AC) circumferences as well as body mass index (BMI) in obese group. Moreover, dyslipidemia, and hyperleptinemia have been demonstrated in obese group. Furthermore, serum malondialdehyde (MDA) and nitric oxide (NO) levels were significantly increased in obese group versus the lean control group. In addition, obese group revealed significant decrease in serum adiponectin level in concomitant with significant increase in resistin level as compared to lean control group. On the other side, treatment with Moringa oleifera alcoholic extract or simvastatin could reduce food intake and BMI as well as ameliorate the dyslipidemia, in obese groups. Serum leptin level showed significant decrease in obese group due to treatment with Moringa oleifera alcoholic extract or Simvastatin. As well significant inhibition of serum MDA and NO levels was detected as a consequence of treatment with either Moringa oleifera extract or Simvastatin. Additionally, the treatment of obese group with Moringa oleifera extract or Simvastatin resulted in significant decrease in serum resistin level in concomitant with significant increase in serum adiponectin level as compared to obese control group. In conclusion, the data of the current study provides experimental evidence for the anti-obesity effect of Moringa oleifera ethanol extract. Thus, present findings reinforce the advice recommending consumption of Moringa oleifera to modulate obesity. | en_US |
| dc.description.sponsorship | International Journal of Pharmaceutical Sciences Review and Research | en_US |
| dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=19700188319&tip=sid&clean=0 | |
| dc.language.iso | en | en_US |
| dc.publisher | International Journal of Pharmaceutical Sciences Review and Research | en_US |
| dc.relation.ispartofseries | Int. J. Pharm. Sci. Rev. Res.,;2 | |
| dc.subject | University of Malondialdehyde | en_US |
| dc.title | Moringa oleifera offers a Multi-Mechanistic Approach for Management of Obesity in Rats | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | https://doi.org/ | |
| dc.Affiliation | October University for modern sciences and Arts (MSA) |
